Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cell Point (India)NSE:CELLPOINT +5.53%72 Debt-to-EBITDA is 6.11 as of Mar. 2026, which is 23% above its 10-year median of 4.98. GuruFocus rates NSE:CELLPOINT with a GF Score™ of 72/100 and a GF Value™ of ₹34.97 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 902 Retail - Cyclical companies, Cell Point (India) ranks worse than 86.36% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Cell Point (India)'s Debt-to-EBITDA or its related term are showing as below:
NSE:CELLPOINT'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 3.14 Med: 4.98 Max: 7.13
Current: 7.13
During the past 7 years, the highest Debt-to-EBITDA Ratio of Cell Point (India) was 7.13. The lowest was 3.14. And the median was 4.98.
NSE:CELLPOINT's Debt-to-EBITDA is ranked worse than 86.36% of 902
companies
in the Retail - Cyclical industry
Industry Median: 2.4
vs NSE:CELLPOINT: 7.13
Cell Point (India) (NSE:CELLPOINT) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Cell Point (India) Debt-to-EBITDA Related Terms
Cell Point (India) Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Cell Point (India)'s Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:CELLPOINT vs CASY, WSM, DKS: Debt-to-EBITDA Comparison
For the Specialty Retail subindustry, Cell Point (India)'s Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cell Point (India) Debt-to-EBITDA vs Retail - Cyclical Industry
For the Retail - Cyclical industry and Consumer Cyclical sector, Cell Point (India)'s Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Cell Point (India)'s Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Mar. 2026) EBITDA data.
Cell Point (India) (NSE:CELLPOINT) has a Debt-to-EBITDA of 6.11 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Cell Point (India). This is 23% above median its historical median of 4.98. Over the past decade, Cell Point (India)'s Debt-to-EBITDA has ranged from 3.14 to 7.13. According to the industry distribution chart, Cell Point (India) ranks #779 out of 902 companies in the Retail - Cyclical industry, placing it in the top 86.4%.
Is Cell Point (India)'s Debt-to-EBITDA too high?
Cell Point (India)'s current Debt-to-EBITDA of 6.11 is 23% above median its 10-year median of 4.98. Over the past 10 years, this metric has ranged from a low of 3.14 to a high of 7.13. The Retail - Cyclical industry median Debt-to-EBITDA is 2.40. Cell Point (India)'s value of 6.11 is 154.6% above this industry median. Based on the distribution chart, Cell Point (India) ranks #779 out of 902 companies in the Retail - Cyclical industry, which is in the bottom quartile relative to peers. Overall, Cell Point (India) has a GF Score™ of 72/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cell Point (India)'s Debt-to-EBITDA compare to CASY and WSM?
According to the Retail - Cyclical industry distribution chart, Cell Point (India) ranks #779 out of 902 companies for Debt-to-EBITDA. This places Cell Point (India) in the lower half of its industry. The industry median Debt-to-EBITDA is 2.40. Cell Point (India)'s value of 6.11 is 154.6% above this benchmark. Historically, Cell Point (India)'s own Debt-to-EBITDA has ranged from 3.14 to 7.13 over the past decade. While the company's 10-year median is 4.98 vs. the industry median of 2.40, Cell Point (India) has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Retail - Cyclical company?
The median Debt-to-EBITDA among Retail - Cyclical companies is 2.40, based on 902 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cell Point (India)'s current Debt-to-EBITDA of 6.11 is 154.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Cell Point (India). For the Retail - Cyclical industry, the median Debt-to-EBITDA is 2.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cell Point (India)'s current Debt-to-EBITDA is 6.11, which is 23% above median its own 10-year median of 4.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cell Point (India) stock overvalued right now?
Based on GuruFocus' analysis, Cell Point (India) (NSE:CELLPOINT) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹34.97, compared to a current price of ₹20.05 — trading 42.7% below its estimated fair value. The current Debt-to-EBITDA is 6.11, which is 23% above median its 10-year median of 4.98 and 154.6% above the Retail - Cyclical industry median of 2.40. Cell Point (India)'s overall GF Score™ is 72/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Cell Point (India) (NSE:CELLPOINT), the current Debt-to-EBITDA is 6.11 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cell Point (India) (NSE:CELLPOINT) Overvalued in 2026?
Based on GuruFocus' analysis, Cell Point (India) stock appears to be undervalued.
The current stock price of ₹20.05 is trading 42.7% below its estimated GF Value™ of ₹34.97.
GuruFocus considers Cell Point (India) to be Significantly Undervalued.
Key valuation signals for NSE:CELLPOINT:
Debt-to-EBITDA: 6.11 (23% above median its 10-year median of 4.98)
GF Value™: ₹34.97 vs. price of ₹20.05 (42.7% below fair value)
Industry Position: 154.6% above the Retail - Cyclical median (#779 of 902)
No single metric tells the full story. See the NSE:CELLPOINT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cell Point (India) Ltd is engaged in multi-brand retail selling of smartphones, tablets, mobile accessories, and mobile-related products of various brands such as Apple, Samsung, Oppo, Realme, Nokia, Vivo, Xiaomi, Nokia, Redmi, Techno, One Plus, etc. It is also engaged in retail selling of consumer durable electronics goods, smart televisions, smart watches, and air conditioners of various brands such as Xiaomi, Realme, and One Plus among others. The company operates in a single segment and derives revenue from its operations in India.
72GF Score
Get the complete analysis for NSE:CELLPOINT
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:CELLPOINT has been successfully added to your 
